Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus Medtech (Hangzhou)VMTHF 52 Equity-to-Asset is 0.70 as of Dec. 2025, which is 3% above its 10-year median of 0.68. GuruFocus rates VMTHF with a GF Score™ of 52/100 and a GF Value™ of $1.27. The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Venus Medtech (Hangzhou) ranks better than 59.91% on this metric.
The historical rank and industry rank for Venus Medtech (Hangzhou)'s Equity-to-Asset or its related term are showing as below:
VMTHF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37 Med: 0.68 Max: 0.89
Current: 0.7
During the past 9 years, the highest Equity to Asset Ratio of Venus Medtech (Hangzhou) was 0.89. The lowest was 0.37. And the median was 0.68.
VMTHF's Equity-to-Asset is ranked better than 59.91% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs VMTHF: 0.70
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Venus Medtech (Hangzhou) Equity-to-Asset Related Terms
Venus Medtech (Hangzhou) Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VMTHF vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Venus Medtech (Hangzhou)'s Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) (VMTHF) has a Equity-to-Asset of 0.70 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Venus Medtech (Hangzhou) and its competitors. This is near median its historical median of 0.68. Over the past decade, Venus Medtech (Hangzhou)'s Equity-to-Asset has ranged from 0.37 to 0.89. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #342 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 40.1%.
Is Venus Medtech (Hangzhou)'s Equity-to-Asset too high?
Venus Medtech (Hangzhou)'s current Equity-to-Asset of 0.70 is near median its 10-year median of 0.68. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 0.89. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Venus Medtech (Hangzhou)'s value of 0.70 is 9.4% above this industry median. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #342 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #342 out of 853 companies for Equity-to-Asset. This puts Venus Medtech (Hangzhou) in the upper half of its industry. The industry median Equity-to-Asset is 0.64. Venus Medtech (Hangzhou)'s value of 0.70 is 9.4% above this benchmark. Historically, Venus Medtech (Hangzhou)'s own Equity-to-Asset has ranged from 0.37 to 0.89 over the past decade. While the company's 10-year median is 0.68 vs. the industry median of 0.64, Venus Medtech (Hangzhou) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Medtech (Hangzhou)'s current Equity-to-Asset of 0.70 is 9.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Venus Medtech (Hangzhou) and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current Equity-to-Asset is 0.70, which is near median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current Equity-to-Asset of 0.70. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current Equity-to-Asset is 0.70, which is near median its 10-year median of 0.68 and 9.4% above the Medical Devices & Instruments industry median of 0.64. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current Equity-to-Asset is 0.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.
Key valuation signals for VMTHF:
Equity-to-Asset: 0.70 (near median its 10-year median of 0.68)
GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
Industry Position: 9.4% above the Medical Devices & Instruments median (#342 of 853)
No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for VMTHF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMTHF has been successfully added to your 
